Volume 2 / Year 2013 / Issue 4
Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?
Abstract: Despite the fact that hepatitis C is a disease of global importance, many countries cannot afford the costly but effective combination treatment of peg-interferon and ribavirin, which was recently… Read More »
Abstract: The Editor-in-Chief expresses his concerns about the proposal of a WHO run system to approve copy biologicals in the Milani and Gaspani paper . The paper by Milani and… Read More »